Esketamine
Imran Qureshi, PharmD, BCPP
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Treatment-resistant depression as monotherapy or adjunct to antidepressant therapy
- MDD with acute suicidal ideation as adjunct to antidepressant therapy
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.